References
- Chang A E, Kinsella T., Glatstein E, et al. Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol 1988; 6: 1491–1500
- Brana M F, Catellano J M, Jimenez A, Lombart A, Rabadan F, Roldan C, Santos A, Vazquez D. Synthesis and mode(s) of action of a new series of imide derivatives of 3-nitro-1, 8-napthalic acid. Cancer Chemother Pharmacol 1980; 4: 61–66
- Waring M J, Gonzalez A, Jimenez A, Vazquez D. Intercalative binding to DNA of antitumor drugs derived from 3-nitro-1, 8-napthalic acid. Nucleic Acids Res 1979; 7: 217
- Hsiang Y-H, Jiang J B, Lui L F. Topoisomerase II-mediated DNA cleavage by amonifide and its structural analogs. Mol Pharmacol 1989; 36: 371–376
- O'Bryan R M, Baker L H, Gottlieb J B, et al. Dose response evaluation of Adriamycin in human neoplasia. Cancer 1977; 39: 1940–1948
- Borden E C, Amato D, Enterline H T, et al. Randomized comparison of Adriamycin regimens for treatment of metastatic soft tissue sarcomas. J Clin Oncol 1987; 5: 840–850
- Schoenfeld D, Rosenbaum C, Horton J, et al. A comparison of Adriamycin versus vincristine and Adriamycin, and cyclophosphamide for advanced sarcoma. Cancer 1982; 50: 2757–2762
- Omura G A, Major F J, Blessing J A, et al. A randomized study of Adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983; 52: 626–632
- Elias A D, Ryan L, Sulkes A, Collins J, Aisner J, Antman K H. Response to mesna, Adriamycin. ifosfamide and DTIC in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989; 7: 1208–1216
- Ratain M J, Mick R, Berezin F, Janisch L, Schilsky R L, Williams S F, Smiddy J. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 1991; 50: 573–579
- Anderson B S, Bakic M, Newman R A, Zwelling L A. Cytotoxic and DNA-cleaving effects of benziosoquinolinedione (nafidimide; NSC-308847) in human leukemia. Proc Am Assoc Cancer Res 1986; 27: 283